摘要
目的:比较不同治疗模式对结直肠癌腹膜转移患者的疗效。方法:回顾性分析2013年1月至2018年3月在武汉大学中南医院治疗的结直肠癌腹膜转移患者的临床及预后资料,按治疗模式分为3组:肿瘤细胞减灭术(CRS)+腹腔热灌注化疗(HIPEC)+全身化疗组;CRS+HIPEC组;单纯全身化疗组,比较不同治疗模式对患者的疗效。结果:CRS+HIPEC+全身化疗组患者的中位生存期为27.5个月,优于其他两组(CRS+HIPEC组:12月,单纯全身化疗组:8月)。多因素分析显示,腹膜癌指数(PCI)≥20分和细胞减灭的程度(CC)>1分是影响肿瘤细胞减灭术+腹腔热灌注化疗治疗结直肠癌腹膜转移预后不良的独立因素。结论:肿瘤细胞减灭术+腹腔热灌注化疗+全身化疗是结直肠癌腹膜转移的最佳治疗模式,可给患者带来最佳的生存获益。
Objective:To investigate the efficacy of different treatment modes on patients with peritoneal car-cinomatosis of colorectal cancer.Methods:Patients with colorectal peritoneal cancer from January 2013 to March 2018 were selected from Zhongnan Hospital of Wuhan University.Patients′overall survival was analyzed based on the treatment they received.Results:Median overall survival was 27.5 months in patients who received cytoreductive surgery(CRS)+hyperthermic intraperitoneal chemotherapy(HIPEC)+chemotherapy,and was longer than 12 months in CRS+HIPEC patients,and 8 months in chemotherapy patients.In multivariate analysis for overall survival,peritoneal carcinoma index(PCI)≥20 and completeness of cytoreduction(CC)>1 were independent prognostic factors for patients received CRS+HIPEC.Conclusion:CRS+HIPEC+chemotherapy is the best treatment option for peritoneal metastasis of colorectal cancer,which can provide the greatest survival benefit to patients.
作者
李仕卿
彭茜
杨朝纲
王舒艺
熊斌
LI Shiqing;PENG Qian;YANG Chaogang;WANG Shuyi;XIONG Bin(Dept.of Gastrointestinal Surgery,Zhongnan Hospital of Wuhan University,Hubei Key Laboratory of Tumor Biological Behaviors,&Hubei Cancer Clinical Study Center,Wuhan 430071,Hubei,China)
出处
《武汉大学学报（医学版）》
CAS
2020年第5期758-762,共5页
Medical Journal of Wuhan University
基金
湖北省卫生健康委科研基金(编号:WJ2019H012)
关键词
腹膜转移癌
结直肠癌
肿瘤细胞减灭术
腹腔热灌注化疗
Peritoneal Metastatic Carcinoma
Colorectal Cancer
Cytoreductive Surgery
Hyperthermic Intraperitoneal Chemotherapy
